ERβ agonists have been reported to exert therapeutic benefits in NASH by directly regulating the functions of xenobiotics and bile acid receptors in the liver, and exert their effects indirectly by inhibiting obesity [41]. Here, NR1H4 is linked to obesity due to melanocortin 4 receptor deficiency.